EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Navigating the AI Transformation in Healthcare

    Real Chemistrys expansion into Zurich is part of our broader objective to help clients by scaling internationally while maintaining a local mindset We are bringing our connected capabilities to one of Europes most influential hotspots sitting at the intersection of science innovation and investment This convergence is ideal for collaboration

KNOWLEDGE BANK

  • Articles

    How Predictive Maintenance Reduces Downtime in Pharma Plants

    The pharmaceutical industry is always under stress to enhance the reliability of the production adherence to the regulations and quality of the products without raising the prices and to maintain a continuous supply Machinery malfunctions are not merely a setback in this highstakes game they may compromise batch integrity postpone life and death treatments and put pressure on the market promises

    What is Clinical Drug Trials and what are the four phases of clinical trials

    In a clinical trial actors admit specific interventions according to the exploration plan or protocol created by the investigators These interventions may be medical products similar as medicines or bias procedures or changes to actors geste similar as diet Clinical trials may compare a new medical approach to a standard bone thats formerly available to a placebo that contains

    Understanding Pharmacodynamics: The Science behind Drug Action Mechanisms

    In the complicated world of pharmacology pharmacodynamics is also a place that is a bridge between chemistry and physiology Drugs do something somewhere and this explains how they do it In a simple way pharmacodynamics studies the action of drugs the effects of drugs in terms of their biochemical and physiological effects and how the effects are generated

    A Closer Look at Pharmacological Interventions: Treatment Overview

    Pharmacological interventions are a cornerstone of modern healthcare encompassing a diverse array of medications designed to treat alleviate or prevent various medical conditions

    The Synergy of Bioinformatics and Computational Biology in Genome Analysis

    In the dynamic field of biological sciences the fusion of bioinformatics and computational biology has catalyzed a paradigm shift in genome analysis This synergistic collaboration harnesses cuttingedge computational tools statistical models

    The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

    The earliest example of in vivo expression of exogenous mRNA was by direct intramuscular injection in mice without the aid of a delivery vehicle This appears to defy what is known about nucleic acids being that they are large polar and metabolically unstable drugs that do not cross cell membranes However since cytoplasmic delivery is essential for mRNA transcription

TOP ARTICLES

press releases Read more...

Cytovance Biologics Expands Process Development Services with Perfusion Capabilities

Cytovance Biologics a leading USbased contract development and manufacturing organization CDMO serving the biopharmaceutical industry today announced the expansion of its upstream process development offerings with the addition of perfusion capabilities

Anova and Nouveau Biosciences Announce Partnership to Deliver Clinical Trials of Kromastat for the Treatment of Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphoma

Anova Enterprises Inc Anova a technology enabled CRO dedicated to accelerating promising treatments today announced its partnership with Nouveau Biosciences Inc to conduct cancer focused

Gerresheimer Commissions Photovoltaic System in Pfreimd

Gerresheimer an innovative system and solution provider and a global partner for the pharma biotech and cosmetic industries has successfully commissioned a photovoltaic system at its Pfreimd site following

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand Pharmaceuticals Incorporated Nasdaq LGND today announced it has completed its acquisition of XOMA Royalty Corporation XOMA Royalty a biotechnology royalty aggregator for per

16 - 19

Jul 2026

Bio Asia Taiwan 2026

Taipei Nangang Exhibition Cent...

20 - 22

Jul 2026

6th mRNA-Based Therapeutics Summit

The Westin Boston Seaport Dist...

20 - 22

Jul 2026

24 - 25

Jul 2026

26 - 30

Jul 2026

ADLM 2026

Anaheim, CA USA

27 - 28

Jul 2026

27 - 28

Jul 2026

27 - 28

Jul 2026

LATEST NEWS Read more...

Sinopia Biosciences Publishes Preclinical Study Supporting SB-0110 for Parkinson's Disease

Sinopia Biosciences has published preclinical research in Science Translational Medicine highlighting a new approach to treating Parkinsons disease The study supports the development of SB

Kairos Pharma Reports Positive Interim Safety Results from Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer

Kairos Pharma has reported positive interim safety results from its ongoing Phase clinical trial of ENV carotuximab in combination with osimertinib Tagrisso for patients with advanced EGFRmutated nonsmall cell lung cancer NSCLC

FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Primary Membranous Nephropathy

Roche has announced that the US Food and Drug Administration FDA has granted Priority Review to its supplemental Biologics License Application sBLA for GazyvaGazyvaro obinutuzumab as a treatment

FDA Grants Fast Track Designation to SOTIO’s SOT109 for Advanced Colorectal Cancer

SOTIO Biotech has received Fast Track Designation FTD from the US Food and Drug Administration FDA for SOT its investigational antibodydrug conjugate ADC for the treatment of patients

Armata Pharmaceuticals Secures FDA Agreement on Initial Paediatric Study Plan for AP-SA02

Armata Pharmaceuticals has received agreement from the US Food and Drug Administration FDA on its Initial Paediatric Study Plan iPSP for APSA supporting the future evaluation of the investigational

DA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease Treatment

Eisai and Biogen have received approval from the US Food and Drug Administration FDA for a supplemental Biologics License Application sBLA for LEQEMBI IQLIK lecanemabirmb a onceweekly subcutaneous injection for the initiation treatment of early Alzheimers disease